Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A superiority, randomized, open-label, multi-center study to compare the efficacy and safety of adjunctive zonisamide vs replacement with zonisamide of the last added antiepileptic drug in patients with partial onset seizures.

Next Previous
Search
Trial Profile

A superiority, randomized, open-label, multi-center study to compare the efficacy and safety of adjunctive zonisamide vs replacement with zonisamide of the last added antiepileptic drug in patients with partial onset seizures.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zonisamide (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADONE
  • Sponsors Eisai S.r.l.

    • Most Recent Events

    • 23 Mar 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 27 Jun 2012 Planned end date changed from 1 May 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 27 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01630057).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top